Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
VX

OTC · VXRT

VAXART INC

Healthcare · Biotechnology

$0.49

Up+$0.00 (+0.00%)

Updated Sep 12, 2026, 3:23 PM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
87.55M
P/E ratio
-1.65
Dividend yield
0.00%
52-week range
— – —
Volume
8.41K
Avg. volume
545.48K

Price performance

VXRT price history

1M range · 0 trading sessions · Daily adjusted prices

VXRT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest VXRT news

The latest Smart Investors Daily articles mentioning VXRT.

Stock researchCompany · Overview

VXRT research

Overview

Company profile and research snapshot.

Company profile

VAXART INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.00
Implied upside
—
Analysts
—
VXRT recent ratings
DateFirmRatingTarget
Mar 27, 2025B. Riley SecuritiesBuy—
Aug 15, 2024OppenheimerOutperform—
Jan 31, 2024B. Riley SecuritiesBuy—
Sep 7, 2023Cantor FitzgeraldOverweight—
Aug 7, 2023Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that a member of its management team will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026. H.C. Wainwright 28th Annual Global Investment ConferenceDate: Monday, September 14Time: 1:00 p.m. – 1:30 p.m.

Yahoo · Aug 26, 2026

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart’s Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS:• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart's oral recombinant norovirus vaccine candidate.• Extended Intellectual Property Protection secured through at least 2036 across

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By